A Study on Impact of Canagliflozin on Health Status Quality of Life and Functional Status in Heart Failure

  • STATUS
    Recruiting
  • End date
    Oct 8, 2021
  • participants needed
    1900
  • sponsor
    Janssen Research & Development, LLC
Updated on 9 May 2021
ejection fraction
heart failure
diuretics
loop diuretic
spironolactone
cardiomyopathy
heart failure with preserved ejection fraction

Summary

The purpose of this study is to determine the superiority of the effectiveness of canagliflozin 100 milligram (mg) daily versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS).

Details
Condition Heart failure, Heart disease, Congestive Heart Failure, Cardiac Disease, cardiac failure, congestive heart disease
Treatment Placebo, Canagliflozin 100 mg
Clinical Study IdentifierNCT04252287
SponsorJanssen Research & Development, LLC
Last Modified on9 May 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note